The Upstate Carolina CCOP has achieved a national reputation for excellence in community cancer care through its 20+ year participation in programs of the National Cancer Institute. In 2003, the UC-CCOP was highlighted by the NCI as one of 27 CCOPs continuously funded since 1983. The UC-CCOP seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research. The ongoing mission of the Upstate Carolina Community Clinical Oncology Program is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally, we strive to provide education about cancer and the NCI clinical trials program. This grant application encompasses and articulates an ever-expanding vision for the UC- CCOP. Goals for this grant cycle include: Increase patient access and accrual to cancer treatment, prevention and control protocols Maintain leadership among national CCOPs in accrual of minorities, women and underserved populations Collaborate with NCI regarding efforts to conduct health disparities research, symptom management, and quality of life studies Update/streamline data management systems that enhance staff efficiency and cost effectiveness Maintain high quality data management Continue as the premier provider of medical and community education for oncology care and clinical trials program Key strategies to achieving the above goals include development of a gastrointestinal center of excellence at Spartanburg Regional Healthcare System with increased emphasis on Gl clinical trials, expanding our nurse navigator program to include lung cancer, partnering with the NCI in the growth of translational research, and utilizing our highly-respected Minority Outreach Coordinator to strengthen and expand partnerships with community organizations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035119-25
Application #
7668675
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1983-09-01
Project End
2012-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
25
Fiscal Year
2009
Total Cost
$1,884,250
Indirect Cost
Name
Spartanburg Regional Medical Center
Department
Type
DUNS #
052072048
City
Spartanburg
State
SC
Country
United States
Zip Code
29303
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95

Showing the most recent 10 out of 202 publications